Current Report Filing (8-k)
January 10 2019 - 4:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): January 10, 2019
Protalix
BioTherapeutics, Inc.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
001-33357
|
|
65-0643773
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
2 Snunit Street
|
|
|
Science Park, POB 455
|
|
|
Carmiel, Israel
|
|
20100
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number,
including area code +972-4-988-9488
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
|
¨
|
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth
company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
|
Item 5.07
|
Submission of Matters
to a Vote of Security Holders
|
Protalix BioTherapeutics, Inc. (the “Company”) held
a Special Meeting of Stockholders on January 10, 2019 (the “Meeting”). At the Meeting, the Company’s stockholders
approved an amendment to the Company’s Certificate of Incorporation, as amended, to increase the number of shares of the
Company’s common stock, par value $0.001 per share, authorized for issuance from 250,000,000 to 350,000,000. Set forth below
are the number of votes cast for and against, and the number of abstentions, for the proposal.
Approval of an amendment to the Company’s
Certificate of Incorporation, as amended, to increase the number of shares our common stock, par value $0.001 per share, authorized
for issuance from 250,000,000 to 350,000,000
For
|
|
Against
|
|
Abstain
|
74,755,268
|
|
14,044,511
|
|
373,156
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PROTALIX BIOTHERAPEUTICS, INC.
|
|
|
|
|
|
Date: January 10, 2019
|
By:
|
/s/ Yossi Maimon
|
|
|
Name:
|
Yossi Maimon
|
|
|
Title:
|
Vice President and
|
|
|
|
Chief Financial Officer
|
|
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Sep 2023 to Sep 2024